Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

383P - A mass spectrometry-based assay for molecular profiling of gliomas and its validation on real-world clinical samples

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Tuo Wang

Citation

Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269

Authors

T. Wang1, F. Tao2, X. Li2, Q. Duan2, S. Chen2, S. Cao2, Y. Ji2

Author affiliations

  • 1 Department Of Neurosurgery, the First Affiliated Hospital of Xi'an Jiaotong University, 710061 - Xi'an/CN
  • 2 Department Of Medicine, Jiangsu Simcere Diagnostics Co., Ltd, 210042 - Nanjing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 383P

Background

Glioma is a common type of brain tumour with a poor prognosis, and its median survival is fewer than 15 months. Accurate molecular profiling may improve outcomes by providing tailored treatments. There are different types of glioma biomarkers, such as point mutations, promoter methylation, and large-scale copy-number variation, which are usually measured by different platforms. To fulfil the clinical requirement of molecular classification of gliomas, we designed an economical and fast assay which can detect biomarkers of multiple types simultaneously, and validated the assay technically and clinically.

Methods

Our assay is based on a mass spectrometry (MS) platform which detects mutations in IDH1-R132, IDH2-R172, TERT-C228T/C250T, H3F3A/HIST1H3B-K27M, and BRAF-V600E, along with MGMT promoter methylation, and chromosomal 1p/19q co-deletion. For technical validation, 60 samples were tested and the results were compared with standard results from NGS/qPCR, FISH, and pyrosequencing. For clinical validation, 1398 real-world samples were curated to evaluate the utility of the assay by assessing the concordance between clinical diagnosis and molecular classification results.

Results

The MS-based assay was validated by the high concordance (greater than 95%) with standard methods. With similar accuracy, the assay takes only half the turnaround time and cost of NGS. Of 1398 cases diagnosed as glioma, our assay correctly subtyped 612 of 646 glioblastomas and 275 of 287 oligodendrogliomas, clinically validated with 95% concordance. 89 cases of 1p/19q co-deletions, 241 positive cases of MGMT promoter methylation, one case of K27M mutation, 19 cases of V600E mutation were detected from 612 consistent glioblastoma samples. Among 34 misclassified glioblastoma samples, 7 cases were detected as co-occurrence of wild-type TERT and IDH mutations, which were suspected as secondary glioblastomas, according to the 2016 WHO classification criteria.

Conclusions

A MS-based assay for molecular profiling of gliomas was designed and validated on more than a thousand real-world clinical samples. The assay is time- and cost-effective, as well as highly accordant with other standard methods and clinical diagnosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.